• Issue

    The Prostate: Volume 83, Issue 1

    1-131
    January 1, 2023
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Page: 1
  • First Published: 07 December 2022

REVIEW ARTICLE

Efficiency and clinical outcomes of Moses technology for holmium laser enucleation of the prostate: An evidence-based analysis

Kangsen Li MM,  Chunyang Meng MM,  Jinze Li MD,  Lijian Gan MM,  Lei Peng MD,  Yunxiang Li MD,  Ji Wu MM, 
  • Pages: 3-15
  • First Published: 21 September 2022

ORIGINAL ARTICLES

Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells

Deepkamal N. Karelia PhD,  Sangyub Kim PhD,  Daniel Plano PhD,  Arun K. Sharma PhD,  Cheng Jiang MD,  Junxuan Lu PhD, 
  • Pages: 16-29
  • First Published: 22 August 2022

Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations

Xiaohao Ruan MD,  Da Huang MD,  Jingyi Huang MD,  Danfeng Xu MD, PhD,  Rong Na MD, PhD, 
  • Pages: 30-38
  • First Published: 22 August 2022

Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates

Jared P. Schober MD,  Kristian D. Stensland MD, MPH,  Alireza Moinzadeh MD, MHL,  David Canes MD,  Jessica Mandeville MD, 
  • Pages: 39-43
  • First Published: 05 September 2022
Open Access

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients

Madhav KC PhD, MPH,  Evrim Oral PhD,  Ariane L. Rung PhD, MPH,  Edward Trapido ScD,  Laura S. Rozek PhD,  Elizabeth T. H. Fontham DrPH,  Jeannette T. Bensen PhD,  Laura Farnan PhD,  Susan E. Steck PhD, MPH,  Lixin Song PhD,  James L. Mohler MD,  Saira Khan PhD, MPH,  Sanah Vohra PhD, MPH,  Edward S. Peters DMD, SM, ScD, 
  • Pages: 44-55
  • First Published: 05 September 2022
Open Access

Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI

Florian A. Schmid MD, PhD,  Laura Lieger MD,  Karim Saba MD,  Silvan Sigg MD,  Fabienne Lehner MD,  Sharon Waisbrod MD,  Alexander Müller MD,  Tullio Sulser MD,  Daniel Eberli MD, PhD,  Ashkan Mortezavi MD, 
  • Pages: 56-63
  • First Published: 08 September 2022

Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis

Emily Chan Brodowsky MD,  Akshay Sood MD,  Mohit Butaney MD,  Sami E. Majdalany MD,  Alex Stephens MS,  Nicholas Corsi BS,  Austin J. Piontkowski BS,  Ivan Rakic BS,  Marcus Jamil MD,  Deepansh Dalela MD,  James O. Peabody MD,  Craig G. Rogers MD,  Firas Abdollah MD, 
  • Pages: 64-70
  • First Published: 19 September 2022

SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer

Rui Lin MM,  Yiping Yang PhD,  Eran Wu MM,  Menghan Zhou BM,  Shan Wang PhD,  Qingyun Zhang PhD, 
  • Pages: 71-81
  • First Published: 08 September 2022

Impact of COVID-19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study

Mehmet Sevim MD,  Okan Alkiş MD,  İbrahim Güven Kartal MD,  Şeref Coşer MD,  Hüseyin Akman MD,  Bekir Aras MD, 
  • Pages: 82-86
  • First Published: 08 September 2022
Open Access

Acute urinary retention in men: 21-year trends in incidence, subsequent benign prostatic hyperplasia-related treatment and mortality: A Danish population-based cohort study

Maria Bisgaard Bengtsen MD,  Uffe Heide-Jørgensen MSc,  Michael Borre MD, PhD,  Jakob S. Knudsen MD, PhD,  Mette Nørgaard MD, PhD, 
  • Pages: 87-96
  • First Published: 20 September 2022

Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer

Shuaibin Wang MD,  Chao Zhang MD, PhD,  Zhifang Xu MD, PhD,  Michael H. Chen,  Haiyan Yu BS,  Lizhong Wang MD, PhD,  Runhua Liu MD, PhD, 
  • Pages: 97-108
  • First Published: 26 September 2022
Open Access

Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies

Wei Ou MD,  Jiahao Lei MBBS,  Minghao Li MBBS,  Xinyao Zhang MMed,  Ruiming Liang MMed,  Lingli Long MD,  Changxuan Wang MBBS,  Lingwu Chen MD,  Junxing Chen MD,  Junlong Zhang MD,  Zongren Wang MD, 
  • Pages: 109-118
  • First Published: 07 October 2022
Open Access

Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study

Yan Hiu Athena Lee,  Jeremy Man Ho Hui,  Jeffrey Shi Kai Chan MBChB,  Kang Liu MD,  Edward C. Dee MD,  Kenrick Ng MA, MBBChir, MRCP, PhD,  Pias Tang MBBS,  Gary Tse MD, PhD, FRCP, FFPH, FRCPath,  Chi Fai Ng MBChB, MD, FRCSEd, FCSHK, FRCSEd (Urol), FHKAM (Surgery), 
  • Pages: 119-127
  • First Published: 30 September 2022

Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer

Ali Mustaffa FRCS, FEB (Urol), SWB (Urol),  Shady Emara PhD, MSc, MRCS, 
  • Pages: 128-131
  • First Published: 29 September 2022